Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection
Journal of Neuropathology & Experimental Neurology · 2025
DOI: 10.1093/jnen/nlaf066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2025. Verfasst von Seong Kwon Hur und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Genentech, Inc., South San Francisco, CA, United States. Hauptthemen laut MEDLINE: Armadillo Domain Proteins, Cytoskeletal Proteins, Action Potentials, Sciatic Nerve. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Genentech.
Abstract (Originalsprache)
The NADase sterile alpha and TIR motif containing 1 (Sarm1) protein drives axon degeneration after injury. Loss or inhibition of Sarm1 structurally protects axons after sciatic nerve transection (SNT) in vivo but whether Sarm1 also drives functional loss after nerve injury is less clear. We established compound muscle action potential (CMAP) as a novel functional correlate of Sarm1 activation in a SNT mouse model and evaluated its relationship with biochemical and a novel Cellpose-based histological axon detection measure. CMAP amplitudes were elicited 8 h post-SNT but reached near-floor levels by 24 h. Decreases in CMAP amplitude are delayed in a gene dose-dependent manner in Sarm1 knockout mice or by pharmacological Sarm1 inhibition. Myelinated axon density, the NAD hydrolysis product cyclic adenosine diphosphate ribose (cADPR), and the axon degeneration plasma biomarker neurofilament light (NfL) were all altered in a Sarm1-dependent manner. In wild type mice, axon density and NfL were altered at time points after that of cADPR and functional loss, indicating that functional deficits preceded structural deficits. We conclude that functional and structural declines after injury are delayed by Sarm1 inhibition and that CMAP measures after SNT can serve as a novel, preclinical, functional, pharmacodynamic readout for Sarm1 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Genentech, Inc., South San Francisco, CA, United States.
- Department of Pathology, Genentech, Inc., South San Francisco, CA, United States.
- Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA, United States.
- Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, CA, United States.
- Department of Transgenic Technology, Genentech, Inc., South San Francisco, CA, United States.
- Department of Translational Imaging, Genentech, Inc., South San Francisco, CA, United States.
ORCID-Profile: Martin Weber
Förderung
- Genentech
Zitieren
APA
Hur, S. K., Leahey, R. R., Geringer, M., Cho, C. H., Hernandez-Barry, H., Pang, J., Sawyer, W. S., Baca, M., Nespi, M., Asuncion, R. R., Choy, M., Maksymetz, J., Vito, S. T., Imperio, J., Stark, K., Green, S. A., Chan, B. K., Xie, L., Ly, J., …, & Weber, M. (2025). Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlaf066
Vancouver
Hur SK, Leahey RR, Geringer M, Cho CH, Hernandez-Barry H, Pang J, et al. Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection. Journal of Neuropathology & Experimental Neurology. 2025. doi:10.1093/jnen/nlaf066
BibTeX
@article{Hur2025,
author = {Hur, Seong Kwon and Leahey, Rebecca R and Geringer, Mitchell and Cho, Chang Hoon and Hernandez-Barry, Hilda and Pang, Jichu and Sawyer, William S and Baca, Miriam and Nespi, Marika and Asuncion, Raymond R and Choy, ManKin and Maksymetz, James and Vito, Stephen T and Imperio, Jose and Stark, Kimberly and Green, Samantha A and Chan, Bryan K and Xie, Luke and Ly, Justin and Nugent, Alicia A and Hofmann, Jeffrey W and Hinz, Flora I and Weber, Martin},
title = {Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2025},
doi = {10.1093/jnen/nlaf066}
}
EUVIMED